Exchange: PNK Industry: Biotechnology
10.00% $1.100
America/New_York / 3 mai 2024 @ 10:55
FUNDAMENTALS | |
---|---|
MarketCap: | 5.77 mill |
EPS: | -0.0300 |
P/E: | -36.67 |
Earnings Date: | Mar 30, 2023 |
SharesOutstanding: | 5.25 mill |
Avg Daily Volume: | 0.0004 mill |
RATING 2024-05-03 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -36.67 | sector: PE -11.58 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -36.67 | industry: PE -107.25 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0184 (-101.68%) $-1.118 |
Date: 2024-05-04 |
Expected Trading Range (DAY) |
---|
$ 1.082 - 1.118 ( +/- 1.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2010-12-31 | Howell Ronald R. | Buy | 0 | |
2009-12-31 | Howell Ronald R. | Buy | 0 | |
2008-12-31 | Howell Ronald R. | Buy | 0 | |
2008-05-09 | Howell Ronald R. | Sell | 0 | Common Stock |
2008-05-09 | Tate Wesley D. | Sell | 0 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 14 transactions |
Buy: 10 400 720 | Sell: 10 338 220 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $1.100 (10.00% ) |
Volume | 0.0003 mill |
Avg. Vol. | 0.0004 mill |
% of Avg. Vol | 71.09 % |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
HST Global, Inc., an integrated health and wellness biotechnology company, develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer worldwide. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancers and other life-threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.